In Brief: Roberts Agrylin
Executive Summary
Roberts Agrylin: Anagrelide reaches "approvable" status at FDA Jan. 29 "for the treatment of patients with essential thrombocythemia to reduce the elevated platelet count and to reduce the risk of thrombosis and to improve associated symptoms," the Eatontown, N.J.-based company said...